ClinicalTrials.Veeva

Menu

Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections

Basilea Pharmaceutica logo

Basilea Pharmaceutica

Status

Conditions

Invasive Fungal Infections

Treatments

Drug: Fosmanogepix solution for infusion
Drug: Fosmanogepix 400 mg tablets

Study type

Expanded Access

Funder types

Industry

Identifiers

NCT06433128
EAP to Fosmanogepix

Details and patient eligibility

About

The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.

Sex

All

Ages

12+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.

Trial contacts and locations

0

Loading...

Central trial contact

Marc Engelhardt; WEP-Clinical Pharmaceutical Services Provider

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems